Search results for " Osteoporotic fractures"

showing 5 items of 5 documents

Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis

2016

Background: Serum uric acid (SUA) accounts for about 50% of extracellular antioxidant activity, suggesting that hyperuricemia may have a protective role in diseases characterized by high levels of oxidative stress, such as osteoporosis. We aimed to meta-analyse data regarding bone mineral density (BMD), osteoporosis and fractures in people with higher SUA vs. lower SUA concentrations. Materials and methods: Two investigators conducted a literature search using PubMed and Scopus, without language restrictions. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were used for BMD; risk ratios (RRs) and adjusted odds ratios (ORs) for cross-sectional data. Most possible adju…

Malemedicine.medical_specialtyBone densityClinical BiochemistryOsteoporosis030209 endocrinology & metabolismBone mineral density; fractures; hyperuricemia; osteoporosis; uric acid; Bone Density; Epidemiologic Methods; Female; Humans; Hyperuricemia; Male; Osteoporosis; Osteoporotic Fractures; Uric AcidhyperuricemiaBiochemistryBone remodelingNO03 medical and health sciences0302 clinical medicineBone mineral density; fractures; hyperuricemia; osteoporosis; uric aciduric acidBone DensityInternal medicinemedicineBone mineral densityHumansHyperuricemiaFemoral neck030203 arthritis & rheumatologyBone mineralbusiness.industryHazard ratioGeneral MedicineOdds ratiofracturesmedicine.diseaseosteoporosismedicine.anatomical_structureEndocrinologyFemalebusinessEpidemiologic MethodsOsteoporotic FracturesBone mineral density fractures hyperuricemia osteoporosis uric acid.
researchProduct

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

2012

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. INTRODUCTION: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. METHODS: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who w…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismONJDentistryOsteoporosis; fractures; biphosphonatesAdministration OralBisphosphonates Nested case–control study Osteonecrosis of the jaw Osteoporotic fracturesOSTEPOROSISRisk AssessmentAssociationADMINSTRATIVE DATABASESnested case-control studySettore MED/28 - Malattie OdontostomatologicheClaims dataMedicineHumansnested case-control study; osteoporotic fractures; osteonecrosis of the jaw; bisphosphonatesWomenbisphosphonatesAgedSecondary preventionAged 80 and overOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryMiddle Agedmedicine.diseaseOral BisphosphonateNecrosiosteonecrosis of the jawItalyClaims DataCase-Control StudiesOrthopedic surgeryBisphosphonates; Osteonecrosis of the jaw; Osteoporotic fractures; Nested case-control studyBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryProfileBisphosphonate therapyMedical Record LinkagebusinessOsteonecrosis of the jawOsteoporotic Fractures
researchProduct

Serum uric acid and incident osteoporotic fractures in old people: The PRO.V.A study

2015

Purpose: Although high serum uric acid (SUA) levels are associated with negative outcomes in older people, recent studies reported that hyperuricemia could help protect against the onset of bone fractures. We consequently examined whether baseline SUA levels were associated with risk of incident osteoporotic fractures in a representative group of elderly people with no fractures or other bone-modifying conditions or drugs at the baseline. Methods: Among 3099 people aged ≥ 65. years initially involved in the PRO.V.A. study, 1586 participants with no prior diagnosis of osteoporotic fractures, and no conditions or medication affecting bone metabolism at the baseline were followed up for 4.4. ±…

Malemedicine.medical_specialtyHistologyPhysiologyEndocrinology Diabetes and MetabolismOsteoporosisserum uric acid (SUA)Bone remodelingchemistry.chemical_compoundAbsorptiometry PhotonElderlySerum uric acidEndocrinologyRisk FactorsInternal medicinemedicineHumansHyperuricemiaAbsorptiometryAgedProportional Hazards Modelsbusiness.industryProportional hazards modelIncidence (epidemiology)IncidenceMedicine (all)Serum uric acidConfoundingmedicine.diseaseCommunity-dwelling adultsPhotonSurgeryUric AcidCommunity-dwelling adults; Elderly; Fractures; Osteoporosis; Serum uric acid; Absorptiometry Photon; Aged; Female; Humans; Incidence; Male; Osteoporosis; Osteoporotic Fractures; Proportional Hazards Models; Risk Factors; Uric Acid; Physiology; Endocrinology Diabetes and Metabolism; Histology; Medicine (all)Diabetes and MetabolismchemistryUric acidOsteoporosisFemalebusinessFracturesOsteoporotic Fractures
researchProduct

Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium

2011

Objective: To address the need for standardization of osteoarthritis (OA) phenotypes by examining the effect of heterogeneity among symptomatic (SOA) and radiographic osteoarthritis (ROA) phenotypes. Methods: Descriptions of OA phenotypes of the 28 studies involved in the TREAT-OA consortium were collected. We investigated whether different OA definitions result in different association results by creating various hip OA definitions in one large population based cohort (the Rotterdam Study I (RSI)) and testing those for association with gender, age and body mass index using one-way ANOVA. For ROA, we standardized the hip-, knee- and hand ROA definitions and calculated prevalence's of RO…

Malenivelrikkomedicine.medical_specialtygenetiikkaBiomedical EngineeringMEDLINEdiagnostiset kriteeritOsteoarthritisbehavioral disciplines and activitiesArticleCohort Studies03 medical and health sciencesRotterdam Study0302 clinical medicineRheumatologyInternal medicineTREATOAOsteoarthritismedicinePrevalenceGeneticsHumansOrthopedics and Sports Medicine030304 developmental biologyRheumatology and Autoimmunity2. Zero hunger030203 arthritis & rheumatology0303 health sciencesAnalysis of Varianceperinnöllisyystiedebusiness.industryCase-control studyDefinitionReference Standardsmedicine.diseaseGenetics Osteoarthritis Phenotype Definition TREATOA genome-wide association radiographic hip osteoarthritis bone-mineral density knee osteoarthritis hand osteoarthritis osteoporotic fractures general-population joint involvement risk-factors susceptibilityRheumatology3. Good healthPhenotypeCase-Control Studiesdiagnostic criteriaCohortPhysical therapyFemalebusinessBody mass indexCohort study
researchProduct

Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

2014

Guidelines for the management of osteoporosis induced by endogenous hypercortisolism are not available. Both the American College of Rheumatology and the International Osteoporosis Foundation recommend to modulate the treatment of exogenous glucocorticoid-induced osteoporosis (GIO) based on the individual fracture risk profile (calculated by FRAX) and dose of glucocorticoid used, but it is difficult to translate corticosteroid dosages to different degrees of endogenous hypercortisolism, and there are no data on validation of FRAX stratification method in patients with endogenous hypercortisolism. Consequently, it is unclear whether such recommendations may be adapted to patients with endoge…

Oncologymedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismOsteoporosisHypercortisolismAdrenal incidentaloma; Cushing's disease; Glucocorticoids; Osteoporosis; Bone Density Conservation Agents; Cushing Syndrome; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Risk FactorsEndogenyDiseaseadrenal incidentalomaBone remodelingRisk FactorsInternal medicinemedicineHumansCushing SyndromeBone Density Conservation Agentsglucocorticoidsbusiness.industrycushing's diseaseCushing's diseasemedicine.diseaseosteoporosisRheumatologyglucocorticoids; osteoporosis; cushing's disease; adrenal incidentalomaEndocrinologyAdrenal incidentaloma; CUSHING'S DISEASE; Glucocorticoids; OsteoporosisbusinessGlucocorticoidOsteoporotic Fracturesmedicine.drug
researchProduct